UBRELVY is the first in its class1,2

An oral acute treatment that works differently at a primary cause of migraine by blocking CGRP receptors without causing vasoconstriction.1,3

Learn about a different mechanism of action

Discover pain relief

See the safety profile
References

1. UBRELVY [package insert]. Madison, NJ: Allergan USA, Inc.; 2019. 2. Data on file. Allergan. 3. Edvinsson L, Haanes KA, Warfvinge K, Krause DN. CGRP as the target of new migraine therapies—successful translation from bench to clinic. Nat Rev Neurol. 2018;14(6):338-350.

This website uses cookies and other technologies to personalize content and to show you more personalized ads (for example, Google Ads and Facebook) on this and other websites, as well as provide you with social media features on this website (such as, Facebook, Twitter, LinkedIn). Read more By clicking “Accept” you understand that you are directing Allergan to disclose your personal information, including internet tracking data (like cookies and the IP address you used to access this website), to these third parties for the purposes stated above.

You can still use this website if you do not click “Accept,” but your experience may be different.

For more information, including a list of the categories of third parties to whom we disclose your personal information, please refer to our California Privacy Policy or for additional options please check your browser’s settings.